Author's response to reviews

Title: Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

Authors:

Charlotte M Huijts (c.huijts@vumc.nl)
Saskia J Santegoets (s.santegoets@vumc.nl)
Alfons J van den Eertwegh (vandeneertwegh@vumc.nl)
Laura S Pijpers (l.pijpers@vumc.nl)
John B Haanen (j.haanen@nki.nl)
Tanja D de Gruijl (td.degruijl@vumc.nl)
Henk M Verheul (h.verheul@vumc.nl)
Hans J van der Vliet (jj.vandervliet@vumc.nl)

Version: 4 Date: 30 November 2011

Author's response to reviews:

Editorial Board
BMC Cancer

Amsterdam, November 30th, 2011

Dear Editor,

We have made some small typographical changes in our manuscript.
- On several pages CD4+CD25+ has been changed into CD4+CD25+.
- On page 14 2nd stage has been changed into 2nd stage.
- On page 15 CD4+CD25+FOXP3+ has been changed into CD4+CD25+FOXP3+.
- On page 17 hematopoietic progenitor cells has been changed into HPCs.

Yours sincerely,

C.M. Huijts, MD
H.J. van der Vliet, MD, PhD

Department of Medical Oncology
VU University medical center
De Boelelaan 1117
1081 HV, Amsterdam, The Netherlands
Email: c.huijts@vumc.nl, jj.vandervliet@vumc.nl